CIP
CRDF icon

Chartwell Investment Partners’s Cardiff Oncology CRDF Stock Holding History

Chartwell Investment Partners’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-296,507
Closed -$652K – 417
2022
Q2 		$652K Buy
296,507
+215,514
+266% +$361K 0.03% 384
2022
Q1 		$201K Buy
80,993
+3,386
+4% +$12K 0.01% 413
2021
Q4 		$466K Buy
+77,607
New +$463K 0.01% 413

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Chartwell Investment Partners's CRDF Position: Q3 2022 in Review

Chartwell Investment Partners sold out of Cardiff Oncology (CRDF) in Q3 2022, closing a stake of 296,507 shares — an estimated $652K sold.

Chartwell Investment Partners first reported a position in CRDF in Q4 2021 and held it in 3 quarters. The position peaked at $652K in Q2 2022. 58 funds tracked by Wall St. Rank hold CRDF as of Q3 2022.

  • Chartwell Investment Partners reported no remaining Cardiff Oncology position as of Q3 2022 after selling out during the quarter.
  • Chartwell Investment Partners sold 296,507 Cardiff Oncology shares in Q3 2022, an estimated $652K.
  • Chartwell Investment Partners first reported a position in Cardiff Oncology in Q4 2021 and held it in 3 quarters.
  • Chartwell Investment Partners's Cardiff Oncology position peaked at $652K in Q2 2022.
  • 58 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2022.

Based on Chartwell Investment Partners's 13F filing for Q3 2022, filed 27 Oct 2022.